DexCom, Inc. (NASDAQ:DXCM – Get Rating) Director Steven Robert Pacelli sold 412 shares of DexCom stock in a transaction dated Friday, December 23rd. The shares were sold at an average price of $112.57, for a total transaction of $46,378.84. Following the completion of the transaction, the director now directly owns 137,288 shares of the company’s stock, valued at approximately $15,454,510.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
DexCom Stock Performance
Shares of NASDAQ:DXCM traded down $1.56 on Tuesday, reaching $109.88. 1,734,000 shares of the company’s stock were exchanged, compared to its average volume of 3,173,238. DexCom, Inc. has a twelve month low of $66.89 and a twelve month high of $143.07. The company has a fifty day moving average of $112.69 and a 200-day moving average of $94.09. The company has a market capitalization of $42.44 billion, a price-to-earnings ratio of 203.87, a PEG ratio of 4.28 and a beta of 1.14. The company has a current ratio of 3.77, a quick ratio of 3.43 and a debt-to-equity ratio of 1.08.
DexCom (NASDAQ:DXCM – Get Rating) last issued its quarterly earnings results on Thursday, October 27th. The medical device company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. DexCom had a return on equity of 13.27% and a net margin of 8.24%. The business had revenue of $769.60 million during the quarter, compared to analysts’ expectations of $752.67 million. On average, research analysts predict that DexCom, Inc. will post 0.79 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently commented on DXCM shares. StockNews.com initiated coverage on DexCom in a report on Wednesday, October 12th. They set a “hold” rating for the company. Cowen boosted their target price on DexCom from $85.00 to $114.00 in a report on Friday, October 28th. Cowen raised their price target on DexCom from $85.00 to $114.00 in a report on Friday, October 28th. Barclays began coverage on shares of DexCom in a research report on Monday, October 17th. They set an “equal weight” rating and a $103.00 price objective for the company. Finally, Jefferies Financial Group started coverage on shares of DexCom in a research report on Wednesday, October 12th. They issued a “buy” rating and a $125.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.53.
Institutional Trading of DexCom
Several large investors have recently modified their holdings of DXCM. E Fund Management Co. Ltd. raised its stake in DexCom by 2.7% in the first quarter. E Fund Management Co. Ltd. now owns 1,378 shares of the medical device company’s stock valued at $705,000 after purchasing an additional 36 shares in the last quarter. Private Portfolio Partners LLC raised its position in shares of DexCom by 11.0% in the 1st quarter. Private Portfolio Partners LLC now owns 495 shares of the medical device company’s stock valued at $253,000 after buying an additional 49 shares in the last quarter. Pinebridge Investments L.P. lifted its holdings in shares of DexCom by 2.3% during the 1st quarter. Pinebridge Investments L.P. now owns 2,453 shares of the medical device company’s stock worth $1,255,000 after acquiring an additional 56 shares during the period. Centaurus Financial Inc. boosted its position in shares of DexCom by 5.5% during the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after acquiring an additional 64 shares in the last quarter. Finally, Raymond James Trust N.A. increased its stake in DexCom by 3.1% in the first quarter. Raymond James Trust N.A. now owns 2,233 shares of the medical device company’s stock valued at $1,142,000 after acquiring an additional 67 shares during the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.